InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,732.93
(
0.25%
)
US TECH 100
19,425.20
(
0.54%
)
Dow Jones
42,208.22
(
0.20%
)
Brent Oil
74.32
(
-0.32%
)
Bitcoin
63,948.18
(
-0.50%
)
Post# of 648882
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Tuff-Stuff

Send PM Follow Ignore
Followers 218
Posts 247348
Boards Moderated 2
Alias Born 04/06/2006

Tuff-Stuff

Re: None

Tuesday, 10/21/2014 7:33:07 AM

Tuesday, October 21, 2014 7:33:07 AM

Post# of 648882
The Dermatologic and Ophthalmic Drugs Advisory Committee votes unanimously in favor of approving Novartis' (NYSE:NVS) interleukin-17A inhibitor secukinumab for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. A final decision by the FDA is expected in early 2015.
Novartis has also submitted its regulatory application with the European Medicines Agency. A decision is expected in late 2014 to early 2015.

Pray for A Pain Free Day!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up